Thursday, December 12, 2019

 


Khiron Life Sciences Corp
(TSX-V: KHRN.VN) Add to Watchlist
$0.950
+0.030 (+3.26%)
as of 16:40 EST

Last 0.950
Change +0.030 (+3.26%)
Open 0.910
Prev. Close 0.920
Today's Range
0.910 0.960
52wk Range
0.790 4.350
Volume 69,871
Avg Volume 332,135

Recent Headlines
-- First Hemp CBD brand to enter Latin American market under Dixie Brands joint venture  (full story)
KHRN.VN: 0.950 (+0.030), KHRNF: 0.7180 (+0.0160)
Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, announces that Mark Monaghan has resigned as a director of the Company and that Deborah Rosati FCPA, FCA, ICD.D has  (full story)
ACB.TO: 3.44 (+0.22), MEDFF: 18.8100 (-0.0700), KHRN.VN: 0.950 (+0.030), KHRNF: 0.7180 (+0.0160)
Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), an integrated cannabis company with core operations in Latin America, announced today that its shares have received Depository Trust Company (DTC) full-service eligibility in the United States.  (full story)
KHRN.VN: 0.950 (+0.030), KHRNF: 0.7180 (+0.0160)
-- Khiron receives conditional TSXV approval for Latin American joint venture with Dixie Brands and U.S. distribution and sale of Kuida cosmeceutical line  (full story)
KHRN.VN: 0.950 (+0.030), KHRNF: 0.7180 (+0.0160), DIXI-U.CN: 0.210 (unch), DXBRF: 0.2120 (+0.0020)
Performance Comparison
Name Today 3-Month 1-Year
KHRN.VN +3.26% -17.39% -33.10%
$TXCX +0.04% +3.90% +14.64%
$TXCI +0.15% +3.85% +14.08%
DJIA +0.79% +7.87% +14.70%
S&P 500 +0.86% +9.73% +19.52%

Key Statistics
Annual EPS -0.400
Dividend & Yield -- (--)
P/E Ratio N/A
Market Capitalization, $K 105,006
Weighted Alpha -58.41
Standard Deviation +0.75
Profit Margin -4.46%
Beta 3.929

Growth Rates
YTD -37.91%
1-Year -28.13%
© 2019 Market data provided and hosted by Barchart Market Data Solutions. Fundamental company data provided by Morningstar and Zacks Investment Research. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.